Alta Life Sciences provides consulting services in the healthcare industry, specifically in pharmaceutical and biotechnology product development and market advisement.

Alta Life Sciences

Alta Life Sciences | 1,544 followers on LinkedIn. https://www.altals.com/ | Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.

Founding Partner at Alta Life sciences

Miguel Valls

Entrepreneur, Venture Capitalist, former GOP Gubernatorial Candidate for Nevada, Philanthropist, Mentor | Media, Radio, and TV Show Contributor

Guy Paul Nohra

Exciting day at the #UglyDuck24 conference! Jose Maria Fernandez and Philippe Monteyne , partners at Aliath, are attending EIF’s flagship #venturecapital conference today! The team is excited to learn and discuss the latest industry trends and future perspectives with thought leaders. Stay tuned for insights on this event! 💡 #AliathBioventures #EIFevent #Innovation #lifesciences

Aliath Bioventures

We are glad to announce that our colleague Montserrat Vendrell , co-founding partner of Aliath Bioventures, participated in the BNEW - Barcelona New Economy Week #BNEW2024 and shared her insights on healthcare innovation. Montserrat joined a session moderated by Santiago de Torres, Executive President of Atrys Health, with Josep Maria Campistol, director of the Hospital Clínic de Barcelona , and Manel del Castillo Rey , director of the Hospital Sant Joan de Déu Barcelona to discuss the transformative role of new technologies in healthcare. Montserrat highlighted the critical role of investors in driving innovation, particularly in disruptive technologies such as #AI , which are revolutionising diagnostics, treatments and the sustainability of healthcare systems. She stressed the importance of analysing these disruptions to understand how the market, hospitals and patients will respond. Supporting technology in healthcare is essential as its impact is far-reaching across the system. The 5th edition of BNEW was a huge success, attracting over 12,700 professionals from 106 countries and facilitating over 10,000 networking connections across seven interconnected sectors - Digital Industry, Mobility, Sustainability, Aviation, Talent, Health and Experience - the event offered a wealth of knowledge. #Innovation #Healthcare #AI #BNEW2024 #Sustainability #Investment #Technology

SPA - Società Prodotti Antibiotici and Inbiomotion sign an exclusive distribution agreement for MAF Test® in Italy SPA - Società Prodotti Antibiotici , a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion , proprietors of MAF Test® for identifying high risk early-stage breast cancer patients, have signed an exclusive distribution agreement to start offering the MAF Test® in Italy. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists identify patients potentially receptive to the prevention of recurrence and who may benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated or are being treated with bisphosphonates. Thanks to this agreement, the MAF Test® could increase the survival of 8 out of 10 of the 55,000 early-stage breast cancer patients diagnosed each year in Italy. Joël Jean-Mairet , Executive Chairperson of Inbiomotion since 2012 and Executive Chairperson of Ysios Capital commented, "We are thrilled to partner with SPA - Società Prodotti Antibiotici to bring the cutting-edge MAF Test® to Italy. This collaboration represents a significant step forward in making precision medicine accessible to more patients. At Inbiomotion , our mission has always been to transform cancer treatment by providing an innovative diagnostic tool that empower both healthcare professionals and patients to make the best possible decisions. By offering a tailored approach to cancer treatment, we can significantly improve patient outcomes, reduce the likelihood of unnecessary treatments, and ultimately enhance the quality of life for those battling breast cancer. We believe that this partnership with SPA - Società Prodotti Antibiotici will play a crucial role in achieving these goals in the Italian market." # PerspectiveFromKnowledge #UncoverTheUndiscovered #CancerDiagnostics #BreastOncology #PrecisionMedicine #PatientJourney For more information: https://lnkd.in/dnerZKxZ

Inbiomotion

INBRAIN Neuroelectronics Announces World’s First Human Graphene-based Brain Computer Interface Procedure INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company pioneering graphene-based neural technologies, announced today the world’s first human procedure of its cortical interface in a patient undergoing brain tumor resection. INBRAIN’s BCI technology was able to differentiate between healthy and cancerous brain tissue with micrometer-scale precision. Read more: https://lnkd.in/dbbddWGZ #INBRAINNeuroelectronics #Graphene INBRAIN Neuroelectronics #braincomputer #braintumor #cancerous #BCItechnology

Nanotechnology Info & Statistics

(ES) ⭐¡Excelentes noticias!⭐ Mejoras y resultados en la app de salud de MAPFRE tras integrar el evaluador de síntomas de Mediktor . (EN ⬇️) ✅ Más de 15.000 clientes han utilizado esta herramienta. ✅ El 92% de los usuarios reporta un alto nivel de satisfacción. ✅ Se ha logrado una mayor empatía con los clientes gracias a la incorporación de un avatar médico interactivo. ✅ Mejora significativa en la atención de salud mental, discapacidades, enfermedades tropicales y del viajero. Este caso de uso es un excelente ejemplo de cómo la #innovación transforma el sector de la salud y mejora la experiencia de los clientes. Si estás buscando esto para tu negocio, deja un comentario para realizar una demo 🙋🏽! - (EN) ⭐Excellent news! ⭐ Great results after MAPFRE integrated Mediktor into their app! ✅ +15K clients have used the tool. ✅ 92% of users reported high satisfaction. ✅ Greater empathy with clients thanks to an interactive medical avatar. ✅ Significant improvement in care for mental health, disabilities, and tropical and travel-related illnesses. An excellent example of how #innovation is transforming healthcare and enhancing the customer experience. If you want to achieve these goals with your company, comment below for a demo 🙋🏽! https://lnkd.in/dktxrz4u https://lnkd.in/eAQcKrYQ https://lnkd.in/ebpn8bx9 https://lnkd.in/eJ4fBrgJ

Mediktor

Today, after several years of constant work, testing, validations, iterations, clinical feedback and an infinite list of supporters and partners, we finally, as a real team, made clinical history on BCI therapeutics. Today, we finally witnessed how graphene unfolds its societal impact!!! This world’s first graphene brain implantation is built from the shoulders of Nobel Laureates Geim & Novoselov, pioneers such as Jose Antonio Garrido , Kostas Kostarelos , Anton Guimerà Brunet and many others and driven by the amazing INBRAIN Neuroelectronics team which grit to a great purpose has been truly admirable. However, the one that beared the whole burden today was Dr. David Coope whose collaboration over the last 3 years has been extraordinary. The INBRAIN Neuroelectronics mission team that led this important first is composed by Maria Ruiz Sanchez-Beato , Damià Viana Casals , Rodrigo Alejandro Pérez & Matteo Donegà who meticulously planned every step to support a seamless procedure Without a doubt the hero of the day was the patient that decided to make history with us for the sake of science and medicine to whom we will be forever thankful Thanks all and thanks as well to our investors Josep Ll. Sanfeliu Asabys Partners , Montserrat Vendrell Aliath Bioventures , Vsquared Ventures TruVenturo GmbH INNVIERTE ECONOMIA SOSTENIBLE COINVERSION SA SCR , ICF, Finaves that have always believed in us with their continuous support This is just the beginning Per áspera ad astra!

Carolina Aguilar

Handelsblatt covers our news today of the first graphene-based #BCI implant. https://lnkd.in/e8viR2Ey

INBRAIN Neuroelectronics

We’re excited to announce today the world’s first human procedure of our graphene-based cortical interface in a patient undergoing brain tumor resection. 🧠🧠 Our BCI tx technology is able to differentiate between healthy and cancerous brain tissue with micrometer-scale precision. The study was sponsored by the The University of Manchester and primarily funded by the European Commission’s Graphene Flagship project. Thank you to Chief Clinical Investigator Dr. David Coope, a neurosurgeon at the Manchester Centre for Clinical Neuroscience and Chief Scientific Investigator Kostas Kostarelos , Ph.D., Professor of Nanomedicine at The University of Manchester, the Catalan Institute of Nanoscience & Nanotechnology, and Co-Founder of INBRAIN. “The world’s first human application of a graphene-based BCI highlights the transformative impact of graphene-based neural technologies in medicine. This clinical milestone opens a new era for BCI technology, paving the way for advancements in both neural decoding and its application as a therapeutic intervention,” said Carolina Aguilar , CEO and Co-Founder of INBRAIN Neuroelectronics. Read the release: 👇👇 https://lnkd.in/eYvtpvrV

⬇ Free Download ⬇ AI in Public Hospitals: A Story of Patient Education and Improved Time Management 👇 Hospital Arnau de Vilanova introduced Mediktor in their waiting rooms to guide low-urgency patients toward better care options. Results were unprecedented. Most patients who completed Mediktor ’s assessment and weren’t suited for the emergency department opted for more appropriate alternatives, reducing pressure on the ED. Learn how these results were achieved by downloading the entire success case here. ➡ https://bit.ly/4eze1OU

Great to represent Aliath Bioventures ( AltamarCAM Partners ) in this panel today with inspiring panelists and a great audience

Metric
Company Name	Alta Life Sciences
Symbol
MSH ID	COM:ALTALIFESCIENCES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare Consulting
Country	US
Stage
Employee Count
Website	altalifesciences.com
LinkedIn	altalifesciences
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ALTA

COM:ALTALIFESCIENCES

Alta Life Sciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue